Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CytoDyn Inc.

< Previous 1 2 3 Next >
News headline image
CytoDyn Announces Appointment of Additional Directors with Industry Experience
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
News headline image
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
News headline image
CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid
From CytoDyn Inc.
Via Business Wire
Tickers CYDY
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS